Nyxoah SA (NYXH) stock
Close on Nov 17, 2026Market cap $38.72MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- €35.09M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.42
- Dividend yield
- –
- Free cash flow yield
- -198.87%
Fundamentals
- Net income
- -€90.09M
- EPS, diluted
- -2.36 EUR
- Free cash flow
- -€69.78M
- Book value per share
- 1.46 EUR
- Diluted shares
- 57M
Trading
- Previous close
- $0.89
- Open
- $0.90
- Day's range
- $0.87 – $0.90
- Volume
- 23,011
- Average volume (20 days)
- 237,845
- RSI (14 days)
- 38.5
- Volatility (1 year)
- 83.7%
- Relative volume
- 0.09×
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | NYXH | S&P 500 | Difference | NYXH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -18.9% | -4.0% | −14.9 pts | ||
| 3 months | -43.8% | -5.0% | −38.8 pts | ||
| Year to date | -80.4% | +8.2% | −88.7 pts | ||
| 1 year | -81.1% | +11.2% | −92.3 pts | ||
| 3 years | -82.1% | +68.5% | −150.6 pts | -43.6% | +19.0% |
| 5 years | -96.1% | +67.3% | −163.3 pts | -47.6% | +10.8% |
Eight years at a glance
Fiscal years 2018 to 2025, EUR
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Nyxoah filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Nyxoah
Surgical & Medical Instruments & Apparatus
Nyxoah is a medical technology company focused on developing and commercializing therapeutic solutions for obstructive sleep apnea. Its primary product is the Genio system, a leadless hypoglossal neurostimulation device that delivers bilateral stimulation to keep upper airways open during sleep. The system is implanted through a single incision under the chin and operates using an external power source. The company primarily targets adult patients diagnosed with moderate to severe obstructive sleep apnea who cannot tolerate, fail, or refuse positive airway pressure therapies, marketed through hospitals and physicians such as sleep specialists and ear, nose, and throat doctors.
Company profile, executives and historyNyxoah stock: common questions
What is Nyxoah's stock price?
NYXH closed at $0.90 on Nov 17, 2026, up 0.69% on the day.
What is Nyxoah's market cap?
Nyxoah was worth $38.72M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is NYXH's P/E ratio?
Nyxoah lost money over fiscal 2025 (diluted EPS -2.36 EUR), so it has no meaningful P/E ratio.
Does Nyxoah pay a dividend?
No. Nyxoah has not paid a cash dividend over the last twelve months.
How has NYXH stock performed over the past year?
Including dividends, NYXH returned -81.1% over the past year, against +11.2% for the S&P 500.
Who are Nyxoah's competitors?
Companies most similar to Nyxoah by business, industry and size include INSP, VVOS, LUNG, CVRX, BWAY.
See a number that looks wrong?